SAB Biotherapeutics

SABS · NASDAQ

$2.88+$0.28 (+10.77%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.60

SABS analyst rating

BuyConsensus of 9 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy9
Hold0
Underperform0
Sell0

12-month price target · 13 analysts

Average $11.87 (+312.1% upside)

Low: $6.06
Now: $2.88
High: $16.80

Upgrades and downgrades

The latest rating actions, newest first

SABS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Jun 24, 2026	Initiates	Overweight	$13.00	45%
Chardan Capital	Jun 17, 2026	Maintains	Buy	$14.00 → $16.00	38%
Leerink Partners	Jun 15, 2026	Maintains	Outperform	$7.00 → $12.00	25%
HC Wainwright & Co.	Jun 15, 2026	Maintains	Buy	$10.00	27%
Citigroup	May 22, 2026	Initiates	Buy	$11.00	36%
Jefferies	May 20, 2026	Initiates	Buy	$11.00	46%
HC Wainwright & Co.	May 12, 2026	Maintains	Buy	$7.00 → $10.00	27%
Rodman & Renshaw	May 11, 2026	Maintains	Buy	$13.00	0%
Rodman & Renshaw	Apr 2, 2026	Initiates	Buy	$13.00	0%
Chardan Capital	Mar 11, 2026	Maintains	Buy	$12.00 → $14.00	38%

The case for and against

Updated Oct 21, 2026

Bull case

SAB Biotherapeutics is attractive because Tzield’s accelerated approval in Stage 3 T1D validates preservation of C-peptide as an approvable endpoint and de-risks SAB-142’s regulatory path. The company’s lead asset has a differentiated profile versus rATG and teplizumab, with early Phase 1 data showing no anti-drug antibodies after redosing through Day 360, preserved Tregs, and predictable PK that supports a 1.5 mg/kg every 6 months maintenance regimen. With an estimated ~1.5 million U.S. T1D patients, ~64,000 new cases per year, and modeled 2035 revenues of ~$2.4 billion, the commercial opportunity appears substantial if the Phase 2b SAFEGUARD study confirms these signals.

Bear case

SAB Biotherapeutics is burdened by a highly speculative, single-asset profile, with valuation tied almost entirely to SAB-142 while the FDA already stopped short of a broader label after key secondary endpoints of PROTECT failed to show reduced HbA1c or lower insulin needs. The company remains clinical-stage, has a history of losses, and expects significant operating losses to continue because research, development, clinical testing, and general and administrative costs will stay high, increasing the need for dilutive equity or restrictive debt financing. Its outlook is further weakened by limited clinical data, regulatory uncertainty, competition from better-resourced peers, no sales or distribution infrastructure, and unique operational risk from maintaining approximately 200 genetically engineered animals at a single South Dakota location.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.